Efficacy of a Phosphorodiamidate Morpholino Oligomer Antisense Compound in the Inhibition of Corneal Transplant Rejection in a Rat Cornea Transplant Model
- 7 December 2011
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 28 (2) , 194-201
Abstract
Purpose: The cornea is one of the most commonly transplanted tissues. The morpholino-oligomer antisense compound AVI-5126 suppresses expression of proto-oncogene c-myc, a key factor in transplant rejection. AVI-5126 was evaluated in a rat cornea transplant model. Methods: Donor corneas obtained from August x Copenhagen Irish rats were stored in Optisol™ containing 1.0 or 0.5 mg/mL AVI-5126 or Optisol alone for 24 h before transplant. Recipient Lewis rats were treated topically 3x/d with TobraDex™ and with 1.0 or 0.5 mg/mL of AVI-5126 or saline with daily monitoring for rejection using a modified McDonald-Shadduck Slit Lamp Scale. Using the high-performance liquid chromatography technique, the stability of AVI-5126 (0.5 mg/mL) in Optisol was evaluated for 30 days. AVI-5126 corneal transport was measured using Ussing chamber mounted rabbit corneas. The potential ocular toxicity of AVI-5126 (0.5 mg/mL) was evaluated after 8 days of 3x/d topical application in rats and in-vitro by incubation of human corneas for 8 days. Results: Cornea storage in Optisol containing 1.0 mg/mL AVI-5126 plus post-transplant topical tid AVI-5126 (1.0 mg/mL) application significantly increased graft survival (7.0±1.6 days) versus 5.0±0.8 days for Optisol alone storage plus post-transplant topical tid saline application ( P Conclusions: Graft rejection was significantly delayed after pretransplantation storage of graft corneas in Optisol containing AVI-5126 followed by topical application of AVI-5126 post-transplantation. AVI-5126 was well tolerated, stable, and effectively penetrated the cornea.Keywords
This publication has 28 references indexed in Scilit:
- Preservation of Human CorneaTransfusion Medicine and Hemotherapy, 2011
- Protection of transplant-induced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway downregulationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Immune Mechanisms of Corneal Allograft RejectionCurrent Eye Research, 2007
- Sustained Intraocular Rapamycin Delivery Effectively Prevents High-Risk Corneal Allograft Rejection and Neovascularization in RabbitsInvestigative Ophthalmology & Visual Science, 2006
- In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid TumorsClinical Cancer Research, 2005
- Advanced c‐myc antisense (AVI‐4126)‐eluting phosphorylcholine‐coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis modelCatheterization and Cardiovascular Interventions, 2004
- Current Practices in the Prevention and Treatment of Corneal Graft RejectionCornea, 1992
- Expression of c- myc protooncogene in primary cultures of human corneal stromal cellsCurrent Eye Research, 1989
- Equivalence of topical clobetasone and dexamethasone in experimental corneal allograft rejection.British Journal of Ophthalmology, 1981
- PREVENTION OF CORNEAL-GRAFT FAILURE WITH THE IMMUNOSUPPRESSIVE DRUG AZATHIOPRINEThe Lancet, 1967